These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

702 related items for PubMed ID: 26552978

  • 1. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
    Nichols K, Chung EK, Knoderer CA, Buenger LE, Healy DP, Dees J, Crumby AS, Kays MB.
    Antimicrob Agents Chemother; 2016 Jan; 60(1):522-31. PubMed ID: 26552978
    [Abstract] [Full Text] [Related]

  • 2. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
    Cies JJ, Shankar V, Schlichting C, Kuti JL.
    Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
    [Abstract] [Full Text] [Related]

  • 3. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.
    Chung EK, Cheatham SC, Fleming MR, Healy DP, Shea KM, Kays MB.
    J Clin Pharmacol; 2015 Aug; 55(8):899-908. PubMed ID: 25823963
    [Abstract] [Full Text] [Related]

  • 4. Dose optimization of piperacillin/tazobactam in critically ill children.
    De Cock PAJG, van Dijkman SC, de Jaeger A, Willems J, Carlier M, Verstraete AG, Delanghe JR, Robays H, Vande Walle J, Della Pasqua OE, De Paepe P.
    J Antimicrob Chemother; 2017 Jul 01; 72(7):2002-2011. PubMed ID: 28387840
    [Abstract] [Full Text] [Related]

  • 5. Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants.
    Chen Y, Lu J, Dong M, Wu D, Zhu Y, Li Q, Chen C, Li Z.
    Eur J Clin Pharmacol; 2016 Dec 01; 72(12):1479-1488. PubMed ID: 27644691
    [Abstract] [Full Text] [Related]

  • 6. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
    Shea KM, Cheatham SC, Smith DW, Wack MF, Sowinski KM, Kays MB.
    Ann Pharmacother; 2009 Nov 01; 43(11):1747-54. PubMed ID: 19809009
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
    Sturm AW, Allen N, Rafferty KD, Fish DN, Toschlog E, Newell M, Waibel B.
    Pharmacotherapy; 2014 Jan 01; 34(1):28-35. PubMed ID: 23864417
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
    Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP.
    J Antimicrob Chemother; 2014 Jan 01; 69(1):176-9. PubMed ID: 23869050
    [Abstract] [Full Text] [Related]

  • 9. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
    Asín-Prieto E, Rodríguez-Gascón A, Trocóniz IF, Soraluce A, Maynar J, Sánchez-Izquierdo JÁ, Isla A.
    J Antimicrob Chemother; 2014 Jan 01; 69(1):180-9. PubMed ID: 23908259
    [Abstract] [Full Text] [Related]

  • 10. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients.
    Cheatham SC, Fleming MR, Healy DP, Chung CE, Shea KM, Humphrey ML, Kays MB.
    Int J Antimicrob Agents; 2013 Jan 01; 41(1):52-6. PubMed ID: 23228881
    [Abstract] [Full Text] [Related]

  • 11. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients.
    Shea KM, Cheatham SC, Wack MF, Smith DW, Sowinski KM, Kays MB.
    Int J Antimicrob Agents; 2009 Nov 01; 34(5):429-33. PubMed ID: 19726163
    [Abstract] [Full Text] [Related]

  • 12. Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.
    Felton TW, Hope WW, Lomaestro BM, Butterfield JM, Kwa AL, Drusano GL, Lodise TP.
    Antimicrob Agents Chemother; 2012 Aug 01; 56(8):4087-94. PubMed ID: 22585219
    [Abstract] [Full Text] [Related]

  • 13. Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections.
    Chen R, Qian Q, Sun MR, Qian CY, Zou SL, Wang ML, Wang LY.
    Eur J Drug Metab Pharmacokinet; 2016 Aug 01; 41(4):363-72. PubMed ID: 25894901
    [Abstract] [Full Text] [Related]

  • 14. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.
    Patel N, Scheetz MH, Drusano GL, Lodise TP.
    Antimicrob Agents Chemother; 2010 Jan 01; 54(1):460-5. PubMed ID: 19858253
    [Abstract] [Full Text] [Related]

  • 15. Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function.
    Thabit AK, Grupper M, Nicolau DP, Kuti JL.
    J Pharm Pract; 2017 Dec 01; 30(6):593-599. PubMed ID: 29121839
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT.
    Shotwell MS, Nesbitt R, Madonia PN, Gould ER, Connor MJ, Salem C, Aduroja OA, Amde M, Groszek JJ, Wei P, Taylor ME, Tolwani AJ, Fissell WH.
    Clin J Am Soc Nephrol; 2016 Aug 08; 11(8):1377-1383. PubMed ID: 27197907
    [Abstract] [Full Text] [Related]

  • 17. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J.
    Int J Antimicrob Agents; 2010 Feb 08; 35(2):156-63. PubMed ID: 20018492
    [Abstract] [Full Text] [Related]

  • 18. Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients.
    Alobaid AS, Wallis SC, Jarrett P, Starr T, Stuart J, Lassig-Smith M, Mejia JL, Roberts MS, Roger C, Udy AA, Lipman J, Roberts JA.
    Antimicrob Agents Chemother; 2017 Mar 08; 61(3):. PubMed ID: 28052849
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia.
    Cies JJ, Jain J, Kuti JL.
    Pediatr Blood Cancer; 2015 Mar 08; 62(3):477-82. PubMed ID: 25328131
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.